Video

Dr Peter Bach Explains Diminishing Returns in Cancer Drugs

While the cost of introductory cancer drugs is increasing rapidly, there has not been a commensurate increase in benefit, according to Peter Bach, MD, with Memorial Sloan Kettering Cancer Center.

Over the years the cost of gaining a year with a new cancer drug has gone up to $8500. However, while the cost of introductory cancer drugs is increasing rapidly, there has not been a commensurate increase in benefit, according to Peter Bach, MD, with Memorial Sloan Kettering Cancer Center.

Healthcare is the only sector where a product is becoming more expensive while being incrementally less efficient, he said.

“What we see is what economists would call ‘diminishing returns,’” Dr Bach said. “Or you could look at it the other way: higher charges for health benefits.”

Related Videos
Shawn Griffin, MD, sitting for a video interview
Kathi Henson, MBA, sitting for a video interview
Mike Fazio, Navista, Cardinal Health
Dr Mingyang Song
Dr K. Vish Viswanath
H. John Beardsley, MBA, and Fauzea Hussain, MPH, sitting for a video interview
Dr Raymond Osarogiagbon
Dr Kimlin Tam Ashing
Dr John Heymach
Related Content
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo